^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MET overexpression

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    14h
    A Real-World, Observational Study of Tepotinib Plus EGFR TKIs Versus Other Systemic Therapies in Patients With EGFR-Mutant, MET IHC 2+ Non-Small Cell Lung Cancer in Third-Line and Later Settings (ChiCTR2600118264)
    P=N/A, N=166, Ethics Committee of Cancer Hospital of Shandong First Medical University; Cancer Hospital of Shandong First Medical University
    New trial • Real-world evidence
    |
    EGFR mutation • MET overexpression
    |
    Tepmetko (tepotinib)
    15h
    A clinical trial of Vebreltinib plus Andamertinib in NSCLC with MET overexpression following EGFR-TKI (ChiCTR2600117889)
    P2, N=37, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New P2 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET overexpression
    |
    vebreltinib (APL-101) • andamertinib (PLB1004)
    3d
    Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • MET overexpression • EGFR exon 20 mutation
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody • VENTANA® MET (SP44) RxDx Assay
    |
    Tagrisso (osimertinib) • Emrelis (telisotuzumab vedotin-tllv)
    13d
    A multi-omics approach to identify the impact of miR-411ed on NSCLC TKI resistance. (PubMed, bioRxiv)
    Using the IsoTar target prediction tool, we identified STAT3 as a key regulator and confirmed STAT3 protein downregulation upon transfection with miR-411ed. We further investigated the effect of miR-411ed in vivo, observing a reduction in tumor size with miR-411ed in combination with Osimertinib but not with miR-411ed or Osimertinib treatment alone, confirming the effectiveness of miR-411ed in TKI response.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    EGFR mutation • MET overexpression • MET expression
    |
    Tagrisso (osimertinib)
    16d
    SAFFRON: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (clinicaltrials.gov)
    P3, N=345, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • MET overexpression
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)
    18d
    Targeting MET in EGFR-mutated NSCLC. (PubMed, J Thorac Oncol)
    Finally, we highlight unresolved challenges including the lack of standardized biomarker thresholds, optimal timing of MET inhibition, and rational sequencing of available agents. As the therapeutic landscape continues to evolve, improved biomarker precision and optimization of treatment strategies will be essential to maximize the benefit of MET-targeted therapies in EGFRm NSCLC.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • MET amplification • MET overexpression • MET mutation
    29d
    A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Avistone Biotechnology Co., Ltd. | Recruiting --> Active, not recruiting | N=264 --> 40
    Enrollment closed • Enrollment change • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET overexpression • MET mutation
    1m
    Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell Lines. (PubMed, Int J Mol Sci)
    This study provides a framework for selecting cell lines that are responsive to each of the 35 anticancer drugs and elucidating their underlying therapeutic mechanisms through follow-up studies. Ultimately, clinical studies are required to confirm the therapeutic efficacy of the selected drugs.
    Clinical • Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18) • CDK12 (Cyclin dependent kinase 12) • CD44 (CD44 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 overexpression • HER-2 overexpression • MET overexpression • FGFR2 overexpression
    1m
    A Novel Zebrafish Liver-Specific Metastasis Model Reveals c-Met as a Driver of Liver Tropism. (PubMed, Liver Int)
    The zLiverMet model successfully mimics intrahepatic metastasis and highlights c-Met as a driver of liver tropism. This zebrafish-based model offers an 'organism-on-a-chip' platform that is rapid, imageable and scalable-bridging in vitro assays and in vivo models for mechanistic and therapeutic studies of liver metastasis.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET overexpression • MET expression
    |
    SU11274
    1m
    Integrative analysis reveals luteolin's molecular targets and mechanisms in pancreatic cancer treatment. (PubMed, Eur J Med Res)
    This study identifies MET as a critical therapeutic target of luteolin in pancreatic cancer, providing mechanistic insights into luteolin's anti-cancer effects via the MET/PI3K/AKT signaling pathway and supporting its potential clinical application.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET overexpression • MET expression
    2ms
    Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=164, Recruiting, Betta Pharmaceuticals Co., Ltd.
    New P1/2 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CLDN18 (Claudin 18)
    |
    HER-2 positive • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • MET exon 14 mutation • MET overexpression • MET mutation
    |
    Ensacove (ensartinib) • pamvatamig (MCLA-129)
    2ms
    A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=140, Not yet recruiting, Chong Kun Dang Pharmaceutical
    New P1/2 trial • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET overexpression • MET expression